Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.

Razavi-Nematollahi L, Ismail-Beigi F.

Curr Diab Rep. 2019 Nov 20;19(11):132. doi: 10.1007/s11892-019-1266-7. Review.

PMID:
31748838
2.

Smoking and Diabetes Control in Adults With Type 1 and Type 2 Diabetes: A Nationwide Study From the 2018 National Program for Prevention and Control of Diabetes of Iran.

Molla GJ, Ismail-Beigi F, Larijani B, Khaloo P, Moosaie F, Alemi H, Mansournia MA, Ghadimi T, Ghaemi F, Nakhjavani M, Esteghamati A.

Can J Diabetes. 2019 Jul 12. pii: S1499-2671(18)31042-6. doi: 10.1016/j.jcjd.2019.07.002. [Epub ahead of print]

PMID:
31494031
3.

Determinants of glycemic control: Phase 2 analysis from nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2018).

Esteghamati A, Ismail-Beigi F, Khaloo P, Moosaie F, Alemi H, Mansournia MA, Afarideh M, Janbabaei Molla G, Ghadimi T, Shadnoush M, Kermanchi J, Ghaemi F.

Prim Care Diabetes. 2019 Aug 8. pii: S1751-9918(19)30207-4. doi: 10.1016/j.pcd.2019.07.002. [Epub ahead of print]

PMID:
31402326
4.

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions.

Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F.

Diabetes Metab Syndr Obes. 2019 Jul 3;12:1001-1012. doi: 10.2147/DMSO.S212715. eCollection 2019.

5.

Disturbances in Insulin-Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes.

Rahhal MN, Gharaibeh NE, Rahimi L, Ismail-Beigi F.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):4949-4966. doi: 10.1210/jc.2019-00286.

PMID:
31162534
6.

A View Beyond HbA1c: Role of Continuous Glucose Monitoring.

Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F.

Diabetes Ther. 2019 Jun;10(3):853-863. doi: 10.1007/s13300-019-0619-1. Epub 2019 Apr 29. Review.

7.

Prolonged Exposure to Insulin Inactivates Akt and Erk1/2 and Increases Pancreatic Islet and INS1E β-Cell Apoptosis.

Rachdaoui N, Polo-Parada L, Ismail-Beigi F.

J Endocr Soc. 2018 Nov 1;3(1):69-90. doi: 10.1210/js.2018-00140. eCollection 2019 Jan 1.

8.

Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25.

9.

DEXAMETHASONE STRESS TEST: A PILOT CLINICAL STUDY FOR IDENTIFICATION OF INDIVIDUALS HIGHLY PRONE TO DEVELOP TYPE 2 DIABETES.

Taheri N, Aminorroaya A, Ismail-Beigi F, Amini M.

Endocr Pract. 2018 Oct 2;24(10):894-899. doi: 10.4158/EP-2018-0188. Epub 2018 Aug 7.

PMID:
30084689
10.

Relationships between cerebral structure and cognitive function in African Americans with type 2 diabetes.

Hughes TM, Sink KM, Williamson JD, Hugenschmidt CE, Wagner BC, Whitlow CT, Xu J, Smith SC, Launer LJ, Barzilay JI, Ismail-Beigi F, Bryan RN, Hsu FC, Bowden DW, Maldjian JA, Divers J, Freedman BI; AA-DHS MIND and ACCORD MIND Investigators.

J Diabetes Complications. 2018 Oct;32(10):916-921. doi: 10.1016/j.jdiacomp.2018.05.017. Epub 2018 May 29.

11.

Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.

Rege NK, Wickramasinghe NP, Tustan AN, Phillips NFB, Yee VC, Ismail-Beigi F, Weiss MA.

J Biol Chem. 2018 Jul 13;293(28):10895-10910. doi: 10.1074/jbc.RA118.003650. Epub 2018 Jun 7.

12.

An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein.

Glidden MD, Aldabbagh K, Phillips NB, Carr K, Chen YS, Whittaker J, Phillips M, Wickramasinghe NP, Rege N, Swain M, Peng Y, Yang Y, Lawrence MC, Yee VC, Ismail-Beigi F, Weiss MA.

J Biol Chem. 2018 Jan 5;293(1):47-68. doi: 10.1074/jbc.M117.808626. Epub 2017 Nov 7.

13.

Solution structure of an ultra-stable single-chain insulin analog connects protein dynamics to a novel mechanism of receptor binding.

Glidden MD, Yang Y, Smith NA, Phillips NB, Carr K, Wickramasinghe NP, Ismail-Beigi F, Lawrence MC, Smith BJ, Weiss MA.

J Biol Chem. 2018 Jan 5;293(1):69-88. doi: 10.1074/jbc.M117.808667. Epub 2017 Nov 7.

14.

Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016).

Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, Saadat M, Esfahani EN, Ganji M, Noshad S, Khajeh E, Ghajar A, Heidari B, Afarideh M, Mechanick JI, Ismail-Beigi F.

Sci Rep. 2017 Oct 18;7(1):13461. doi: 10.1038/s41598-017-13379-z.

15.

The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study.

Cukierman-Yaffe T, Gerstein HC, Miller ME, Launer LJ, Williamson JD, Horowitz KR, Ismail-Beigi F, Lazar RM.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3218-3225. doi: 10.1210/jc.2016-3480.

16.

Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials.

Ismail-Beigi F, Moghissi E, Kosiborod M, Inzucchi SE.

J Gen Intern Med. 2017 Sep;32(9):1044-1051. doi: 10.1007/s11606-017-4061-7. Epub 2017 May 26. Review.

17.

Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes.

Hashemi Madani N, Ismail-Beigi F, Khamseh ME, Malek M, Ebrahimi Valojerdi A.

Eur J Prev Cardiol. 2017 Jul;24(11):1181-1189. doi: 10.1177/2047487317707293. Epub 2017 Apr 27.

PMID:
28447480
18.

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048. No abstract available.

19.

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators.

JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828. Erratum in: JAMA Cardiol. 2017 Apr 1;2(4):461.

20.

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798. Epub 2016 Jul 27.

21.

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial.

Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, Cantley L, Devarajan P, Parikh CR, Coca SG.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1343-52. doi: 10.2215/CJN.12051115. Epub 2016 May 17.

22.

Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.

Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, Chen SH, Ambrosius WT, Thomas A, Bestermann W, Buse JB, Genuth S, Joyce C, Kovacs CS, O'Connor PJ, Sigal RJ, Solomon S; ACCORD Investigators.

Diabetes Care. 2015 Nov;38(11):2000-8. doi: 10.2337/dc15-0598. Epub 2015 Oct 13.

23.

Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.

Zonszein J, Lombardero M, Ismail-Beigi F, Palumbo P, Foucher S, Groenewoud Y, Cushing G, Wajchenberg B, Genuth S; Bari 2D Study Group.

J Diabetes Res. 2015;2015:129891. doi: 10.1155/2015/129891. Epub 2015 May 27.

24.

Aromatic anchor at an invariant hormone-receptor interface: function of insulin residue B24 with application to protein design.

Pandyarajan V, Smith BJ, Phillips NB, Whittaker L, Cox GP, Wickramasinghe N, Menting JG, Wan ZL, Whittaker J, Ismail-Beigi F, Lawrence MC, Weiss MA.

J Biol Chem. 2014 Dec 12;289(50):34709-27. doi: 10.1074/jbc.M114.608562. Epub 2014 Oct 10.

25.

Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial.

Zhang Z, Lovato J, Battapady H, Davatzikos C, Gerstein HC, Ismail-Beigi F, Launer LJ, Murray A, Punthakee Z, Tirado AA, Williamson J, Bryan RN, Miller ME.

Diabetes Care. 2014 Dec;37(12):3279-85. doi: 10.2337/dc14-0973. Epub 2014 Sep 29.

26.

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.

Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT; Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group.

Ophthalmology. 2014 Dec;121(12):2443-51. doi: 10.1016/j.ophtha.2014.07.019. Epub 2014 Aug 29.

27.

The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial.

Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, Greven C, Schubart U, Buse J.

J Diabetes Complications. 2014 Nov-Dec;28(6):874-9. doi: 10.1016/j.jdiacomp.2014.07.001. Epub 2014 Jul 12.

28.

Risk of insulin accumulation (stacking) with use of novel ultralong-acting insulin formulations.

Bansal V, Davis GM, Ismail-Beigi F.

Endocr Pract. 2014 Sep;20(9):990-1. doi: 10.4158/EP14144.CO. No abstract available.

PMID:
25100381
29.

Protective hinge in insulin opens to enable its receptor engagement.

Menting JG, Yang Y, Chan SJ, Phillips NB, Smith BJ, Whittaker J, Wickramasinghe NP, Whittaker LJ, Pandyarajan V, Wan ZL, Yadav SP, Carroll JM, Strokes N, Roberts CT Jr, Ismail-Beigi F, Milewski W, Steiner DF, Chauhan VS, Ward CW, Weiss MA, Lawrence MC.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):E3395-404. doi: 10.1073/pnas.1412897111. Epub 2014 Aug 4.

30.

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.

Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, Booth GL; ACCORD Study Group.

Lancet. 2014 Nov 29;384(9958):1936-41. doi: 10.1016/S0140-6736(14)60611-5. Epub 2014 Jul 31.

31.

Biophysical optimization of a therapeutic protein by nonstandard mutagenesis: studies of an iodo-insulin derivative.

Pandyarajan V, Phillips NB, Cox GP, Yang Y, Whittaker J, Ismail-Beigi F, Weiss MA.

J Biol Chem. 2014 Aug 22;289(34):23367-81. doi: 10.1074/jbc.M114.588277. Epub 2014 Jul 3.

32.

Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.

Punthakee Z, Miller ME, Simmons DL, Riddle MC, Ismail-Beigi F, Brillon DJ, Bergenstal RM, Savage PJ, Hramiak I, Largay JF, Sood A, Gerstein HC; ACCORD Group of Investigators.

Diabetologia. 2014 Oct;57(10):2030-7. doi: 10.1007/s00125-014-3318-5. Epub 2014 Jul 2.

33.

Dexamethasone-induced insulin resistance: kinetic modeling using novel PET radiopharmaceutical 6-deoxy-6-[(18)F]fluoro-D-glucose.

Su KH, Chandramouli V, Ismail-Beigi F, Muzic RF Jr.

Mol Imaging Biol. 2014 Oct;16(5):710-20. doi: 10.1007/s11307-014-0737-0.

34.

PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.

Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, Calabrese JR.

CNS Drugs. 2014 Jun;28(6):571-81. doi: 10.1007/s40263-014-0158-2.

35.

Human radiation dosimetry of 6-[18F]FDG predicted from preclinical studies.

Muzic RF Jr, Chandramouli V, Huang HM, Wu C, Hatami A, Ismail-Beigi F.

Med Phys. 2014 Mar;41(3):031910. doi: 10.1118/1.4866217.

36.

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB.

Diabetes Care. 2014;37(3):686-93. doi: 10.2337/dc13-0790. Epub 2013 Dec 2.

37.

Albuminuria and cognitive decline in people with diabetes and normal renal function.

Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, Papademetriou V, Launer LJ.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1907-14. doi: 10.2215/CJN.11321112. Epub 2013 Aug 29.

38.

Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND.

Seaquist ER, Miller ME, Fonseca V, Ismail-Beigi F, Launer LJ, Punthakee Z, Sood A.

J Diabetes Complications. 2013 Sep-Oct;27(5):485-91. doi: 10.1016/j.jdiacomp.2013.03.005. Epub 2013 May 13.

39.

Impact of quality mentorship on achievements of Shiraz Medical School in the 1970s and the role of Professors Khosrow Nasr and Asghar Rastegar.

Ismail-Beigi F, Ghahramani N.

Arch Iran Med. 2013 Apr;16(4):251-3. doi: 013164/AIM.0014. No abstract available.

40.

Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.

Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J; BARI 2D Study Group.

J Diabetes Complications. 2014 Jan-Feb;28(1):101-9. doi: 10.1016/j.jdiacomp.2013.01.006. Epub 2013 Mar 7.

41.

Hypoglycemia: minimizing its impact in type 2 diabetes.

Moghissi E, Ismail-Beigi F, Devine RC.

Endocr Pract. 2013 May-Jun;19(3):526-35. doi: 10.4158/EP13005.RA. Review.

PMID:
23425655
42.

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.

Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group.

Diabetes Care. 2013 Aug;36(8):2162-8. doi: 10.2337/dc12-1391. Epub 2013 Feb 14.

43.

Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial.

Gerstein HC, Ambrosius WT, Danis R, Ismail-Beigi F, Cushman W, Calles J, Banerji M, Schubart U, Chew EY; ACCORD Study Group.

Diabetes Care. 2013 May;36(5):1266-71. doi: 10.2337/dc12-1311. Epub 2012 Dec 13.

44.

Hyperglycemia-induced stimulation of glucose transport in skeletal muscle measured by PET-[18F]6FDG and [18F]2FDG.

Huang HM, Chandramouli V, Ismail-Beigi F, Muzic RF.

Physiol Meas. 2012 Oct;33(10):1661-73. Epub 2012 Sep 18.

45.

Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes.

Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M.

Endocr Pract. 2012 Nov-Dec;18(6):826-33. doi: 10.4158/EP12064.OR.

PMID:
22784842
46.

Effect of dexamethasone on glucose homeostasis in normal and prediabetic subjects with a first-degree relative with type 2 diabetes mellitus.

Taheri N, Aminorroaya A, Ismail-Beigi F, Amini M.

Endocr Pract. 2012 Nov-Dec;18(6):855-63. doi: 10.4158/EP12057.OR.

PMID:
22784841
47.

α-Helical element at the hormone-binding surface of the insulin receptor functions as a signaling element to activate its tyrosine kinase.

Whittaker J, Whittaker LJ, Roberts CT Jr, Phillips NB, Ismail-Beigi F, Lawrence MC, Weiss MA.

Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11166-71. doi: 10.1073/pnas.1205681109. Epub 2012 Jun 26.

48.

Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data.

Bonds DE, Miller ME, Dudl J, Feinglos M, Ismail-Beigi F, Malozowski S, Seaquist E, Simmons DL, Sood A.

BMC Endocr Disord. 2012 May 30;12:5. doi: 10.1186/1472-6823-12-5.

49.

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.

Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR.

Arch Intern Med. 2012 May 28;172(10):761-9. doi: 10.1001/archinternmed.2011.2230. Review. Erratum in: Arch Intern Med. 2012 Jul 23;172(14):1095.

50.

A controlled trial of CPAP therapy on metabolic control in individuals with impaired glucose tolerance and sleep apnea.

Weinstock TG, Wang X, Rueschman M, Ismail-Beigi F, Aylor J, Babineau DC, Mehra R, Redline S.

Sleep. 2012 May 1;35(5):617-625B. doi: 10.5665/sleep.1816.

Supplemental Content

Loading ...
Support Center